Phase 1 N=12 The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers
Opiod Use Disorder
Primary: Pharmacokinetics - Time to Maximum Concentration of Midazolam Alone — 0.58 hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=116 Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)
Solid Tumor
Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 1 N=15 CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: CS-7017-Related Treatment-Emergent Adverse Events Occurring During the Study of Administration of CS-7017 Combined With Erlotinib in Participants With Metastatic or…
Phase 1 N=22 Dolutegravir Pediatric Liquid Formulation Study
HIV Infections
Primary: Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Time Point (AUC[0-t]) for DTG — 11.9968; 13.7921; 12.1944 Hours*micrograms per…
Phase 1 N=9 Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis
Lung Cancer · Metastatic Cancer
Primary: The Number of Patients With a Response (Complete Response and Partial Response) — 8 Participants
Phase 1 N=21 Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Primary: Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL. — 3; 2 Participants
Phase 1 N=31 Biological Signatures, Probiotic Among Those With mTBI and PTSD
Mild Traumatic Brain Injury · Post Traumatic Stress Disorder
Primary: C-Reactive Protein Change — 0.113; -0.625 mg/L — p=.056
Phase 1 N=7 Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Recommended Phase 2 Dose of BI 836826 in Combination With Ibrutinib
Phase 1 N=2 Dose Escalation PfSPZ-CVac
Malaria
Primary: Number of Participants With P.Falciparum Blood Stage Infection — 0; 0; 0; 0 Participants
Phase 1 N=19 Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects
Cholestasis
Primary: Part A- Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-t]) for Total-OCA at Steady State: OCA Arm — 2329.804…
Phase 1 N=57 Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects
Healthy Volunteers
Primary: Change-From-Baseline QTcF at Dose Level B Measured on 12-Lead ECGs Extracted From Continuous Recordings — -0.1; -0.6; -0.1; 0.1 ms
Phase 1 N=38 Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)
Shigellosis · Bacillary Dysentery
Primary: Number of Treatment Related Adverse Events — 27; 37; 41; 46 Adverse Events
Phase 1 N=12 A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris
Psoriasis
Primary: Pharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Single Dose) — 6.90 Microgram per milliliter (ug/mL)
Phase 1 N=22 IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
Cancer of the Liver · Liver Cancer · Hepatoma
Primary: Number of Participants With Dose Limiting Events to Determine the Maximum Tolerated Dose (MTD) of Salmonella Typhimurium — 0; 0; 0; 0 Participants
Phase 1 N=52 Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection
HIV Infections
Primary: Number of Infants Who Died or Had Grade 3/4 Adverse Event Through 6 Weeks of Life — 2; 2; 4; 7 Participants